Skip to content

Effects of probiotics on upper respiratory tract infections in adults during influenza season: a randomized, double-dose, placebo-controlled study

Effects of probiotics on upper respiratory tract infections in adults during influenza season: a randomized, double-dose, placebo-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038143
Enrollment
Unknown
Registered
2020-09-11
Start date
2020-09-15
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper respiratory infection

Interventions

The control group:Take a placebo once a day
The experimental group:Take a probiotic once a day

Sponsors

Affiliated Hospital of Inner Mongolia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Volunteers over 20 years old; 2. People who are satisfied with physical health (BMI in normal range); 3. Subjects without serious diseases; 4. Those who are willing to make a commitment to the whole experiment; 5. People who have had a cold at least once in the past year.

Exclusion criteria

Exclusion criteria: 1. The subjects with chronic respiratory tract allergy (defined as daily use of allergic drugs); 2. The subjects of severe gastrointestinal diseases at present; 3. Subjects in pregnancy or lactation period; 4. Subjects who had a cold on the first day of the study; 5. Those who suffered from immunosuppressive diseases or received relevant treatment in the past year; 6. Subjects who received antibiotic treatment within 2 months before the start of the study; 7. People who have been vaccinated with influenza vaccine in the past 12 months; 8. Subjects allergic to any ingredient contained in the preparation, including milk allergy; 9. Subjects of oral corticosteroids; 10. Subjects who regularly took probiotic products (more than three times a week) three weeks before the start of the study.

Design outcomes

Primary

MeasureTime frame
Metagenomics;Metabonomics;Immunity index;

Countries

China

Contacts

Public ContactZhao Jianmin

Affiliated Hospital of Inner Mongolia Medical University

nmzjmin@163.com+86 471-3451005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026